Pilot study of vitamin D supplementation in adults with cystic fibrosis pulmonary exacerbation: A randomized, controlled trial

Ruth E Grossmann, Susu M Zughaier, Meena Kumari, Shabnam Seydafkan, Robert H Lyles, Shuling Liu, Viranuj Sueblinvong, Michael S Schechter, Arlene A Stecenko, Thomas R Ziegler, Vin Tangpricha, Ruth E Grossmann, Susu M Zughaier, Meena Kumari, Shabnam Seydafkan, Robert H Lyles, Shuling Liu, Viranuj Sueblinvong, Michael S Schechter, Arlene A Stecenko, Thomas R Ziegler, Vin Tangpricha

Abstract

<u>

Background: </u> Vitamin D insufficiency is common in cystic fibrosis (CF) and vitamin D repletion may have an important role in improving clinical outcomes in CF. This randomized, placebo-controlled, pilot study examined the feasibility and impact of a single, large dose of cholecalciferol on vitamin D status and clinical outcomes in subjects with CF. <u>

Methods: </u> Thirty adults with were randomized in a double-blinded, pilot study to receive 250,000 IU cholecalciferol or placebo within 48 h of hospital admission for a pulmonary exacerbation. Concentrations of 25-hydroxyvitamin D (25(OH)D), clinical outcomes and potential adverse events were assessed up to one year after randomization. Mixed effects linear regression models were used to evaluate the difference in mean serum concentrations and log-rank analyses were used to evaluate survival. <u>

Results: </u> Data from all subjects was analyzed. Serum 25(OH)D concentrations increased from a mean of 30.6 ± 3.2 ng/mL to 58.1 ± 3.5 ng/mL (p < 0.001) at one week and 36.7 ± 2.6 ng/mL by 12 weeks (p = 0.06) in the vitamin D group; in contrast, serum 25(OH)D concentrations remained unchanged in the placebo group. Unadjusted, one-year survival and hospital-free days were increased in the vitamin D group (p = 0.029, p = 0.036; respectively). There was also a trend toward increased IV antibiotic therapy-free days in the vitamin D group (p = 0.073). There were no signs of hypervitaminosis D or adverse events. Serum PTH and calcium concentrations were similar across both groups. <u>

Conclusions: </u> In this pilot study, a single, oral bolus of cholecalciferol increased serum 25(OH)D concentrations and was associated with a trend toward improved clinical outcomes in CF subjects hospitalized for a pulmonary exacerbation. Further investigation is needed into the clinical impact of improved vitamin D status in patients with CF.

Keywords: anti-microbial peptide; cystic fibrosis; parathyroid hormone; pulmonary exacerbation; vitamin D.

Figures

https://www.ncbi.nlm.nih.gov/pmc/articles/instance/3427199/bin/de-4-191-g3.jpg
Figure 2. Survival analysis by treatment group. The dashed line (vitamin D group) and solid line (placebo group) represent the unadjusted survival curves of adult CF patients (n = 30) randomized to either a single, oral 250,000 IU dose of cholecalciferol or identically matched placebo. Mortality was determined by CF clinic records over the following 12 mo. Subjects receiving cholecalciferol had a significantly increased survival over placebo (Log-rank analysis, p = 0.029). When adjusted for age and FEV1% of predicted, there continued to be a trend for increased survival in the vitamin D group (Log-rank analysis, p = 0.09).
https://www.ncbi.nlm.nih.gov/pmc/articles/instance/3427199/bin/de-4-191-g1.jpg
Figure 3. Recruitment and allocation of subjects. Subjects were recruited from the Emory Adult CF Center within 48 h of admission to the Emory University Hospital for the treatment of an acute pulmonary exacerbation. A total of 34 subjects were assessed for eligibility, 4 were ineligible and 30 subjects were block randomized to either 250,000 IU vitamin D3 or placebo. All subject deaths were related to complications of cystic fibrosis. All patients were followed for 1-y or until death and data from all patients was analyzed for this study.
https://www.ncbi.nlm.nih.gov/pmc/articles/instance/3427199/bin/de-4-191-g2.jpg
Figure 1. Unadjusted, mean change in 25-hydroxyvitamin D in response to a bolus dose of 250,000 IU of vitamin D3 or placebo. The dashed line (vitamin D group) and solid line (placebo group) represent the unadjusted mean change in serum 25-hydroxyvitamin D concentrations [25(OH)D] at baseline, 1 week and 12 weeks in adult CF subjects randomized to either a single 250,000 IU dose of cholecalciferol or placebo. The change in mean serum 25(OH)D from baseline in the vitamin D group was +27.5 (± 13) ng/mL and +6.2 (± 11) ng/mL at week 1 and 12, respectively; contrasted to the change from baseline in the placebo group of -0.2 (± 13) ng/mL and -0.6 (± 14) ng/mL at week 1 and 12, respectively. (Mean with standard error bars, comparison between groups of the change from baseline at week 1, p < 0.001; at week 12, p = 0.06, Student’s t-test).

References

    1. Foundation, Fibrosis C. Patient Registry 2009 Annual Report ed. Bethesda, MD, USA: Cystic Fibrosis Foundation 2010.
    1. Boyle MP, Noschese ML, Watts SL, Davis ME, Stenner SE, Lechtzin N. Failure of high-dose ergocalciferol to correct vitamin D deficiency in adults with cystic fibrosis. Am J Respir Crit Care Med. 2005;172:212–7. doi: 10.1164/rccm.200403-387OC.
    1. Wolfenden LL, Judd SE, Shah R, Sanyal R, Ziegler TR, Tangpricha V. Vitamin D and bone health in adults with cystic fibrosis. Clin Endocrinol (Oxf) 2008;69:374–81. doi: 10.1111/j.1365-2265.2008.03216.x.
    1. Khazai NB, Judd SE, Jeng L, Wolfenden LL, Stecenko A, Ziegler TR, et al. Treatment and prevention of vitamin D insufficiency in cystic fibrosis patients: comparative efficacy of ergocalciferol, cholecalciferol, and UV light. J Clin Endocrinol Metab. 2009;94:2037–43. doi: 10.1210/jc.2008-2012.
    1. Hall WB, Sparks AA, Aris RM. Vitamin d deficiency in cystic fibrosis. Int J Endocrinol. 2010;2010:218691. doi: 10.1155/2010/218691.
    1. West NE, Lechtzin N, Merlo CA, Turowski JB, Davis ME, Ramsay MZ, et al. Appropriate goal level for 25-hydroxyvitamin D in cystic fibrosis. Chest. 2011;140:469–74. doi: 10.1378/chest.10-2114.
    1. Pincikova T, Nilsson K, Moen IE, Karpati F, Fluge G, Hollsing A, et al. Scandinavian Cystic Fibrosis Study Consortium Inverse relation between vitamin D and serum total immunoglobulin G in the Scandinavian Cystic Fibrosis Nutritional Study. Eur J Clin Nutr. 2011;65:102–9. doi: 10.1038/ejcn.2010.194.
    1. Kamen DL, Tangpricha V. Vitamin D and molecular actions on the immune system: modulation of innate and autoimmunity. J Mol Med (Berl) 2010;88:441–50. doi: 10.1007/s00109-010-0590-9.
    1. Urashima M, Segawa T, Okazaki M, Kurihara M, Wada Y, Ida H. Randomized trial of vitamin D supplementation to prevent seasonal influenza A in schoolchildren. Am J Clin Nutr. 2010;91:1255–60. doi: 10.3945/ajcn.2009.29094.
    1. Jeffery LE, Burke F, Mura M, Zheng Y, Qureshi OS, Hewison M, et al. 1,25-Dihydroxyvitamin D3 and IL-2 combine to inhibit T cell production of inflammatory cytokines and promote development of regulatory T cells expressing CTLA-4 and FoxP3. J Immunol. 2009;183:5458–67. doi: 10.4049/jimmunol.0803217.
    1. Stenbit A, Flume PA. Pulmonary complications in adult patients with cystic fibrosis. Am J Med Sci. 2008;335:55–9. doi: 10.1097/MAJ.0b013e31815d2611.
    1. Liu PT, Stenger S, Li H, Wenzel L, Tan BH, Krutzik SR, et al. Toll-like receptor triggering of a vitamin D-mediated human antimicrobial response. Science. 2006;311:1770–3. doi: 10.1126/science.1123933.
    1. Adams JS, Ren SY, Liu PT, Chun RF, Lagishetty V, Gombart AF, et al. Vitamin d-directed rheostatic regulation of monocyte antibacterial responses. J Immunol. 2009;182:4289–95. doi: 10.4049/jimmunol.0803736.
    1. Belderbos ME, Houben ML, Wilbrink B, Lentjes E, Bloemen EM, Kimpen JL, et al. Cord blood vitamin D deficiency is associated with respiratory syncytial virus bronchiolitis. Pediatrics. 2011;127:e1513–20. doi: 10.1542/peds.2010-3054.
    1. Boucher BJ. The 2010 recommendations of the American Institute of Medicine for daily intakes of vitamin D. Public Health Nutr. 2011;14:740–50. doi: 10.1017/S136898001100022X.
    1. Holick MF, Binkley NC, Bischoff-Ferrari HA, Gordon CM, Hanley DA, Heaney RP, et al. Endocrine Society Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2011;96:1911–30. doi: 10.1210/jc.2011-0385.
    1. Green D, Carson K, Leonard A, Davis JE, Rosenstein B, Zeitlin P, et al. Current treatment recommendations for correcting vitamin D deficiency in pediatric patients with cystic fibrosis are inadequate. J Pediatr. 2008;153:554–9. doi: 10.1016/j.jpeds.2008.04.058.
    1. Boas SR, Hageman JR, Ho LT, Liveris M. Very high-dose ergocalciferol is effective for correcting vitamin D deficiency in children and young adults with cystic fibrosis. J Cyst Fibros. 2009;8:270–2. doi: 10.1016/j.jcf.2009.04.004.
    1. Wasse H, Huang R, Long Q, Singapuri S, Raggi P, Tangpricha V. Efficacy and safety of a short course of very-high-dose cholecalciferol in hemodialysis. Am J Clin Nutr. 2012;95:522–8. doi: 10.3945/ajcn.111.025502.
    1. Leventis P, Kiely PDW. The tolerability and biochemical effects of high-dose bolus vitamin D2 and D3 supplementation in patients with vitamin D insufficiency. Scand J Rheumatol. 2009;38:149–53. doi: 10.1080/03009740802419081.
    1. Ferguson JH, Chang AB. Vitamin D supplementation for cystic fibrosis. Cochrane Database Syst Rev. 2009:CD007298.
    1. Green DM, Leonard AR, Paranjape SM, Rosenstein BJ, Zeitlin PL, Mogayzel PJ., Jr. Transient effectiveness of vitamin D2 therapy in pediatric cystic fibrosis patients. J Cyst Fibros. 2010;9:143–9. doi: 10.1016/j.jcf.2010.01.002.
    1. Kerem E, Reisman J, Corey M, Canny GJ, Levison H. Prediction of mortality in patients with cystic fibrosis. N Engl J Med. 1992;326:1187–91. doi: 10.1056/NEJM199204303261804.
    1. de Boer K, Vandemheen KL, Tullis E, Doucette S, Fergusson D, Freitag A, et al. Exacerbation frequency and clinical outcomes in adult patients with cystic fibrosis. Thorax. 2011;66:680–5. doi: 10.1136/thx.2011.161117.
    1. Ginde AA, Scragg R, Schwartz RS, Camargo CA., Jr Prospective study of serum 25-hydroxyvitamin D level, cardiovascular disease mortality, and all-cause mortality in older U.S. adults. J Am Geriatr Soc. 2009;57:1595–603. doi: 10.1111/j.1532-5415.2009.02359.x.
    1. Braun A, Chang D, Mahadevappa K, Gibbons FK, Liu Y, Giovannucci E, et al. Association of low serum 25-hydroxyvitamin D levels and mortality in the critically ill. Crit Care Med. 2011;39:671–7. doi: 10.1097/CCM.0b013e318206ccdf.
    1. Melamed ML, Michos ED, Post W, Astor B. 25-hydroxyvitamin D levels and the risk of mortality in the general population. Arch Intern Med. 2008;168:1629–37. doi: 10.1001/archinte.168.15.1629.
    1. Zittermann A, Iodice S, Pilz S, Grant WB, Bagnardi V, Gandini S. Vitamin D deficiency and mortality risk in the general population: a meta-analysis of prospective cohort studies. Am J Clin Nutr. 2012;95:91–100. doi: 10.3945/ajcn.111.014779.
    1. Proesmans M, Els C, Vermeulen F, De Boeck K. Change in IgG and evolution of lung function in children with cystic fibrosis. J Cyst Fibros. 2011;10:128–31. doi: 10.1016/j.jcf.2010.12.004.
    1. McNally P, Coughlan C, Bergsson G, Doyle M, Taggart C, Adorini L, et al. Vitamin D receptor agonists inhibit pro-inflammatory cytokine production from the respiratory epithelium in cystic fibrosis. J Cyst Fibros. 2011;10:428–34. doi: 10.1016/j.jcf.2011.06.013.
    1. Stephenson A, Brotherwood M, Robert R, Atenafu E, Corey M, Tullis E. Cholecalciferol significantly increases 25-hydroxyvitamin D concentrations in adults with cystic fibrosis. Am J Clin Nutr. 2007;85:1307–11.
    1. Finklea JD, Grossmann RE, Tangpricha V. Vitamin D and chronic lung disease: a review of molecular mechanisms and clinical studies. Adv Nutr. 2011;2:244–53.
    1. Førli L, Bjortuft O, Boe J. Vitamin D status in relation to nutritional depletion and muscle function in patients with advanced pulmonary disease. Exp Lung Res. 2009;35:524–38. doi: 10.1080/01902140902763193.
    1. Moher D, Hopewell S, Schulz KF, Montori V, Gøtzsche PC, Devereaux PJ, et al. CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials. BMJ. 2010;340:c869. doi: 10.1136/bmj.c869.
    1. Bian ZX, Shang HC. CONSORT 2010 statement: updated guidelines for reporting parallel group randomized trials. Ann Intern Med. 2011;154:author reply291–2.
    1. Aris RM, Merkel PA, Bachrach LK, Borowitz DS, Boyle MP, Elkin SL, et al. Guide to bone health and disease in cystic fibrosis. J Clin Endocrinol Metab. 2005;90:1888–96. doi: 10.1210/jc.2004-1629.

Source: PubMed

Sponsors et collaborateurs

Les conditions médicales

Interventions en matière de drogue

3
S'abonner